课题基金 / 基金详情

Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse

Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse
治疗 HIV 相关神经认知障碍的蛋白质组学新方法
批准号:
10097476
负责人:
STUART A LIPTON
金额:
$44.37万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2021-02-28

项目摘要

项目成果

STUART A LIPTON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
AD-Related Administrative Supplement for DP1 DA041722, “Aberrant protein S-nitrosylation mediates synaptic and neuronal toxicity in hiPSC-based models of Lewy Body Dementia (LBD)” SUMMARY Lewy body dementia (LBD), classified as an Alzheimer’s disease (AD)-related dementia, represents the second most common form of neurodegenerative disease after AD in patients above 65 years of age. The key pathological hallmark of LBD entails accumulation of a-synuclein (αSyn) inclusions, although amyloid-β (Aβ) and tau pathologies are also typical, suggesting that there are common pathways contributing to dementia in both LBD and AD. In fact, in LBD and AD brains, synaptic injury and neuronal damage result, at least in part, from excessive generation of reactive oxygen and nitrogen species (ROS/RNS) engendered by toxic subspecies of αSyn and/or Aβ. We were the first group to show that aberrant protein S-nitrosylation (forming SNO-proteins), via RNS (e.g., nitric oxide [NO]) generation, results in synaptic/neuronal damage. Similar to our findings in the parent DP1 grant in human postmortem brains from patients with HIV-associated cognitive disorder with methamphetamine drug abuse (HAND/meth), for this supplemental proposal we present evidence for aberrantly S-nitrosylated proteins in LBD hiPSC models and LBD human brain. Hence, this supplemental application relates to the parent DP1 grant; moreover, the new work complements but is totally distinct from our work on AD human iPSCs and AD brain in a prior supplement to the parent NIDA DP1 award. As an example, our preliminary data provide evidence that mitochondrial-related protein S-nitrosylation of PINK1, MEF2C and Drp1 plays a causative role in disease- related damage in LBD. Specifically, we demonstrate that prevention of these aberrant protein S-nitrosylation reactions ameliorates the disease process, largely abrogating mitochondrial dysfunction, synaptic damage, and neuronal loss in both cell-based and animal models manifesting misfolded αSyn. Accordingly, we propose the following Specific Aim for this Supplemental Application: Specific Aim 1: To determine the effects of oligomeric αSyn and Aβ on SNO-PINK1/SNO-MEF2C/SNO- Drp1—mediated synaptic dysfunction and neuronal cell death in hiPSC-derived neuronal culture models of LBD. We will introduce non-nitrosylatable mutant PINK1, MEF2C, or Drp1 via CRISPR/Cas9 in order to test whether SNO-PINK1, SNO-MEF2C, and SNO-Drp1 contribute in a causal manner to synaptic injury and neuronal cell death. Importantly, we will compare the effects of oligomeric αSyn/Aβ on hiPSC-derived cortical neurons vs. A9 dopaminergic neurons since LBD may preferentially affect cerebrocortex over substantia nigra, respectively.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
  • 批准号:
    10686979
  • 项目类别:
  • 资助金额:
    $45.25万
  • 财政年份:
    2022
  • 负责人:
    STUART A LIPTON
  • 依托单位:
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
  • 批准号:
    10515987
  • 项目类别:
  • 资助金额:
    $44.38万
  • 财政年份:
    2022
  • 负责人:
    STUART A LIPTON
  • 依托单位:
Leadership in AD/ADRD Drug Discovery
  • 批准号:
    10193424
  • 项目类别:
  • 资助金额:
    $106.26万
  • 财政年份:
    2021
  • 负责人:
    STUART A LIPTON
  • 依托单位:
Leadership in AD/ADRD Drug Discovery
  • 批准号:
    10687169
  • 项目类别:
  • 资助金额:
    $108.36万
  • 财政年份:
    2021
  • 负责人:
    STUART A LIPTON
  • 依托单位:
海外基金